GSK to nearly double cancer drugs in trials next year, WSJ reports

SENSEX 73,553.53

 -53.22

NIFTY 22,749.70

 -3.50

CRUDEOIL 9,729.00

+ 6.00

GOLD 142,236.00

 -837.00

SILVER 192,750.00

 -3,043.00

SENSEX 73,553.53

 -53.22

NIFTY 22,749.70

 -3.50

NIFTY 22,749.70

 -3.50

CRUDEOIL 9,729.00

+ 6.00

CRUDEOIL 9,729.00

+ 6.00

GOLD 142,236.00

 -837.00

'; } document.getElementById("lgdv").innerHTML = htmlElements; } function numberformat(i) { return Number(parseFloat(i).toFixed(2)).toLocaleString('en', { minimumFractionDigits: 2 }) } async function gatherResponse(response) { const { headers } = response; const contentType = headers.get('content-type') || ''; if (contentType.includes('application/json')) { return await response.json() } return response.text(); } function getWidth() { if (Math.max(document.body.scrollWidth,document.documentElement.scrollWidth,document.body.offsetWidth,document.documentElement.offsetWidth,document.documentElement.clientWidth) > 991) { document.getElementById("mob").style.display = "none"; document.getElementById("lgdv").style.display = "block"; } else { document.getElementById("mob").style.display = "block"; document.getElementById("lgdv").style.display = "none"; } } getWidth(); THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.

In July, GSK said it expected to have more than 20 late-stage studies by the end of 2026, with three of the seven drugs identified for faster development ‌being cancer medicines

By Reuters

Updated - October 27, 2026 at 03:25 PM.

GSK expects to nearly ​double the number of cancer medicines it ‌is testing in clinical trials next year, ​the Wall Street Journal ⁠reported on Tuesday, citing an interview with a scientist at the British drugmaker.

Hesham Abdullah, ‌GSK's head of oncology research and development, told the WSJ that ‌the company's clinical-stage portfolio of about 15 ‌assets ⁠is likely to come close ⁠to doubling in 2027

According to the report, Abdullah said GSK could have 19 to 20 late-stage ​oncology studies underway ‌next year, with drug candidates being moved straight from early-stage to late-stage studies to speed development

​The drugmaker's oncology push is part of CEO Luke Miels' effort ⁠to reassure investors that GSK can navigate a looming patent cliff for its ‌blockbuster HIV drugs

In July, GSK said it expected to have more than 20 late-stage studies by the end of 2026, with three of the seven drugs identified for faster development ‌being cancer medicines

The company is rebuilding its ​oncology portfolio after exiting the space more than a decade ago, ⁠with cancer drugs such as ris-rez and mo-rez ⁠at the centre of its strategy

Its oncology segment contributed £1.08 ‌billion ($1.44 billion) in the first half of 2026.

Published on October 27, 2026

THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS. THIS AD SUPPORTS OUR JOURNALISM. SUBSCRIBE FOR MINIMAL ADS.Sign into Unlock benefits!

• Access 10 free stories per month
• Get notified by email for early preview to new features, discounts & offers